Maculopapular drug eruption with histopathological features of psoriasiform drug eruption in a patient with psoriasis vulgaris: a case report
Abstract
Maculopapular drug eruption in patient with psoriasis are rarely reported and require close monitoring during oral corticosteroid therapy due to the potential risk of flare following dose reduction or discontinuation. A 47-yo male with a history of psoriasis vulgaris on cyclosporine therapy developed erythematous patches with scaling following the administration of amoxicillin, mefenamic acid, and antitetanus injection after a nail puncture injury. Vital signs were within normal limits. Dermatological examination revealed multiple well-demarcated erythematous macules, patches, and papules with geographic patterns measuring 0.6×0.9 cm to 2.5×4 cm, some confluent, accompanied by white scales and desquamation. Histopathological findings were consistent with psoriasiform drug eruption. The Naranjo score for amoxicillin was 4, showed a possible correlation. A diagnosis of maculopapular drug eruption suspected to be induced by amoxicillin was established. Clinical improvement observed following the administration of oral corticosteroids, cyclosporine, antihistamines, and emollients. The diagnosis of maculopapular drug eruption requires correlation of rash onset and drug initiation as well as monitoring of symptom resolution after drug discontinuation the suspected drug. Histopathological examination may support the diagnosis, with the presence of eosinophils serving as an indicator of drug-induced etiology. Management of maculopapular drug eruption in patients with psoriasis includes withdrawal of the suspected causative agent, symptomatic therapy, systemic corticosteroids, and immunosuppressive treatment as indicated.
References
Heelan K, Sibbald C, Shear NH. Cutaneous reactions to drugs. in Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine. 9th eds. New York: McGraw Hill. 2019. 749-750.
Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F, et al. Mild cutaneous reactions to drugs. Acta Biomed 2019;90(3-S):36-43.
Ernst M, Giubellino A. Histopathologic features of maculopapular drug eruption. Dermatopathology (Basel) 2022;9(2):111-21.
https://doi.org/10.3390/dermatopathology9020014
Singer S, Shihab N, Lebwohl M. Cyclosporine for severe drug eruption in a psoriasis patient. SKIN J Cutan Med 2020;4(4): 388-9.
https://doi.org/10.25251/skin.4.4.23
Shukla AK, Jhaj R, Misra S, Ahmed SN, Nanda M, Chaudhary D. Agreement between WHOUMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care 2021;10(9):3303-8.
https://doi.org/10.4103/jfmpc.jfmpc_831_21
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th eds. London: Elsevier. 2018.
Patterson J. Weedon's skin pathology. 5th eds. London: Elsevier. 2021
Calonje JE, Brenn T, Lazar AJ, McKee PH. Pathology of the skin. E-Book. 5th eds. London: Elsevier Health Sciences. 2020
Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol 2023;14:1071983.
https://doi.org/10.3389/fimmu.2023.1071983
Mantri SS, Ballam Nagaraj N, Patel C, Solanki K, Rana H. Exanthematous drug eruption to intravenous iron: a case report. Cureus 2022;14(2):e22045.
https://doi.org/10.7759/cureus.22045
Oguro, T. Nakajima K, Aoki N, Yamamoto M, Sano S. A case of psoriasiform drug eruption caused by temozolomide. J Cutan Immunol Allergy 2022;5:179-83.
https://doi.org/10.1002/cia2.12263
Horiuchi Y. Psoriasiform eruptions: an etiological perspective. Am J Dermatopathol 2023 Sep 1;45(9):671-3.
https://doi.org/10.1097/DAD.0000000000002509
Kulduk G, Yalçın Ö, Erdem ZB, Karabıyık Altıok D, Topal İO. Maculopapular drug eruptions: Diversity of histopathological changes. Eur Arc Med Res 2023; 39(2): 79-83.
https://doi.org/10.4274/eamr.galenos.2022.27147
Gregoire ARF, DeRuyter BK, Stratman EJ. Psoriasis flares following systemic glucocorticoid exposure in patients with a history of psoriasis. JAMA Dermatol 2021;157(2):198-201.
https://doi.org/10.1001/jamadermatol.2020.4219
Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol 2022;47(5):918-25.



